ArticleeLife2021
Visualization of stem cell activity in pancreatic cancer expansion by direct lineage tracing with live imaging.
Article in eLife, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 27 citations in OpenAlex.
- Evolutionarily Conserved Epigenetic Regulation of Transcriptional Cell States During Vertebrate Pancreatic Tumorigenesis.Cellular and molecular gastroenterology and hepatology · 2026Article
- Downregulation of Sod2 increases atypical flat lesions and dysplasia to advance pancreatic ductal adenocarcinoma.Molecular cancer · 2025Article
- Next generation lineage tracing and its applications to unravel development.NPJ systems biology and applications · 2025Review
- Imaging Approaches in Cancer Biology.Cold Spring Harbor perspectives in medicine · 2024Review
- PanIN and CAF transitions in pancreatic carcinogenesis revealed with spatial data integration.Cell systems · 2024Article
- Acinar-to-Ductal Metaplasia (ADM): On the Road to Pancreatic Intraepithelial Neoplasia (PanIN) and Pancreatic Cancer.International journal of molecular sciences · 2023Review
- Tumor microenvironment interactions with cancer stem cells in pancreatic ductal adenocarcinoma.Advances in cancer research · 2023Review
- SPINOPHILIN: A multiplayer tumor suppressor.Genes & diseases · 2023Review
- The roles of intratumour heterogeneity in the biology and treatment of pancreatic ductal adenocarcinoma.Oncogene · 2022Review
- Review
- Towards 'end-to-end' analysis and understanding of biological timecourse data.The Biochemical journal · 2022Article
- Pleiotropic effects of DCLK1 in cancer and cancer stem cells.Frontiers in molecular biosciences · 2022Review
- Challenges in precision medicine in pancreatic cancer: A focus in cancer stem cells and microbiota.Frontiers in oncology · 2022Review
- 3D Cell Culture Models as Recapitulators of the Tumor Microenvironment for the Screening of Anti-Cancer Drugs.Cancers · 2021Review
- SNAIL2 contributes to tumorigenicity and chemotherapy resistance in pancreatic cancer by regulating IGFBP2.Cancer science · 2021Article
- Article
- Epithelial memory of inflammation limits tissue damage while promoting pancreatic tumorigenesis.Science (New York, N.Y.) · 2021Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 2 countries.
Funding
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease. Although rigorous efforts identified the presence of 'cancer stem cells (CSCs)' in PDAC and molecular markers for them, stem cell dynamics in vivo have not been clearly demonstrated. Here we focused on Doublecortin-like kinase 1 (Dclk1), known as a CSC marker of PDAC. Using genetic lineage tracing with a dual-recombinase system and live imaging, we showed that Dclk1
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.